

Coronavirus (COVID-19) Current Therapy Market Outlook Is Being Shaped By Antibody Therapy

The Business Research Company's COVID-19 Current Therapy Market 2022 – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, June 24, 2022 /EINPresswire.com/ --

Monoclonal antibody therapy is a major trend being followed to develop a short-term way to treat people with

COVID-19. Monoclonal antibody therapy involves the infusion of monoclonal antibodies that are similar to the ones synthesized in the human body naturally in response to infection. These are designed in the laboratory to recognize a specific component of this virus and interfere with the virus activity that attaches and enters into human cells. According to the [coronavirus \(COVID-19\) current therapy market research](#), in this approach of antibody therapy, researchers started isolating antibodies from recovering patients and identifying the best that can neutralize the virus and keeping it from replicating; they then produced these antibodies in bulk in the laboratory.

The continued outbreaks of COVID-19 are expected to contribute to the [coronavirus \(COVID-19\) current therapy market growth](#) during the forecast period. As there is no officially approved drug for COVID-19 therapy, the demand has risen significantly for repurposed drugs that are used for corona therapy. Therefore, these outbreaks will promote the growth of the coronavirus current therapy market.

Read More On The Global Coronavirus (COVID-19) Current Therapy Market Report

<https://www.thebusinessresearchcompany.com/report/coronavirus-covid-19-current-therapy-market>

The global coronavirus (COVID-19) current therapy market size reached a value of nearly \$23.47 billion in 2020. The global coronavirus (COVID-19) current therapy market share is expected to decline from \$23.47 billion in 2020 to \$2.35 billion in 2025 at a rate of -36.9%.



The Business
Research Company

Coronavirus (COVID-19) Current Therapy Market 2022
- Global Forecast To 2030

Major players covered in the global coronavirus (COVID-19) current therapy industry are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc.

TBRC's coronavirus (COVID-19) current therapy market analysis report is segmented by drug type into antiviral, monoclonal antibodies, corticosteroid, supplements, antimalarial, interferons, interleukin inhibitors, other anti-infective drugs, others, by end user into hospitals, clinics, home care, others.

Coronavirus (COVID-19) Current Therapy Market 2022 – By Drug Type (Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other), By End User (Hospitals, Clinics, Home Care, Others), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides a coronavirus (COVID-19) current therapy market overview, forecast coronavirus (COVID-19) current therapy market size and growth for the whole market, coronavirus (COVID-19) current therapy market segments, geographies, coronavirus (COVID-19) current therapy global market trends, coronavirus (COVID-19) current therapy market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Coronavirus (COVID-19) Current Therapy Market Report
<https://www.thebusinessresearchcompany.com/sample.aspx?id=6183&type=smp>

Not What You Were Looking For? Here Is A List Of Similar Reports By The Business Research Company:

Antivirals Global Market Report 2022 – By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza), By Type (Branded, Generic) – Market Size, Trends, And Global Forecast 2022-2026
<https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report>

Hospital Acquired Infections Testing Kits Global Market Report 2022 – By Product (Instrument & Reagents, Consumables), By Test Type (Pneumonia Infection, Urinary Tract Infection, Blood Stream Associated Infection, Surgical Site Infection, MRSA Infection), By Application (Drug-Resistance Testing, Disease Testing), By Pathogen Type (Viral, Bacterial, Fungal), By Method Of Treatment (Sterilization, Chemical, Radiation) – Market Size, Trends, And Global Forecast 2022-2026
<https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report>

COVID-19 Drug Associated APIs Global Market Report 2022 – By Drug Class (Antimalarials, Bronchodilators, Antibiotics, Antivirals), By Source (Microorganisms, Animals, Plants), By Synthesis Type (Synthetic, Biotech), By Business Mode (Captive API, Merchant API) – Market Size,

Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read More About Us At <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call Us Now For Personal Assistance With Your Purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check Out Our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/578267122>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.